Invex Therapeutics Advances Exenatide Development
Invex Therapeutics Ltd. (AU:IXC) has released an update. Invex Therapeutics Ltd has concluded its Phase III IIH EVOLVE clinical trial and is now fo...#invextherapeuticsltd #ixc #phaseiiiiihevolve (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
Can a GLP-1 Agonist Improve Parkinson's Symptoms?
(MedPage Today) -- An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson's disease symptoms compared with... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 20, 2023 Category: Endocrinology Source Type: news
Science ’s 2023 Breakthrough of the Year: Weight loss drugs with a real shot at fighting obesity
Show / hide sections navigation
2023 Breakthrough of the Year
Runners-up
Breakdowns
Video
Obesity plays out as a private struggle and a public health crisis. In the United States, about 70% of adults are affected by excess weight, and in Europe that number is more than half. The stigma against fat can be crushing; its risks, life-threatening. Defined as a body mass index of at least 30, obesity is thought to power type 2 diabetes, heart disease, arthritis, fatty liver disease, and certain cancers.
Yet drug treatments...
Source: ScienceNOW - December 14, 2023 Category: Science Source Type: news
Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice - Coulter-Parkhill A, Tanday N, Cobice D, McLaughlin CM, McClean S, Gault VA, Irwin N.
AIM: The aim of the present study was to assess the long-term therapeutic efficacy of a recently discovered 28 amino acid peptide, Δ-theraphotoxin-Ac1 (Δ-TRTX-Ac1), originally isolated from venom of the Aphonopelma chalcodes tarantula. Δ-TRTX-Ac has previo... (Source: SafetyLit)
Source: SafetyLit - October 16, 2023 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news
FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D
An implanted device for delivering the GLP-1 receptor agonist exenatide to people with type 2 diabetes received a unanimous no vote from an FDA advisory panel based on safety and other concerns.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 22, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Hot weight loss drugs tested as addiction treatments
When the diabetes treatments known as GLP-1 analogs reached the market in 2005, doctors advised patients taking the drugs that they might lose a small amount of weight. Talk about an understatement. Obese people can drop more than 15% of their body weight, studies have found, and two of the medications are now approved by the U.S. Food and Drug Administration (FDA) for weight reduction. A surge in demand for the drugs as slimming treatments has led to shortages. “This class of drugs is exploding in popularity,” says clinical psychologist Joseph Schacht of the University of Colorado School of Medicine.
But patient...
Source: ScienceNOW - August 28, 2023 Category: Science Source Type: news
Hot weight loss drugs tested as addiction treatments
When the diabetes treatments known as GLP-1 analogs reached the market in 2005, doctors advised patients taking the drugs that they might lose a small amount of weight. Talk about an understatement. Obese people can drop more than 15% of their body weight, studies have found, and two of the medications are now approved by the U.S. Food and Drug Administration (FDA) for weight reduction. A surge in demand for the drugs as slimming treatments has led to shortages. “This class of drugs is exploding in popularity,” says clinical psychologist Joseph Schacht of the University of Colorado School of Medicine.
But patient...
Source: ScienceNOW - August 28, 2023 Category: Science Source Type: news
Diabetes Drug Promising for Idiopathic Intracranial Hypertension Diabetes Drug Promising for Idiopathic Intracranial Hypertension
In a small phase 2 trial, subcutaneous exenatide led to a significant reduction in intracranial pressure and number of monthly headaches in patients with IIH.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 16, 2023 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
Effects of Dapagliflozin and Exenatide in T2D Effects of Dapagliflozin and Exenatide in T2D
A new study provides insight into the weight-lowering mechanisms of dapagliflozin and exenatide in obese patients with type 2 diabetes.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Exenatide Linked to Less Hyperglycemia After Stroke Exenatide Linked to Less Hyperglycemia After Stroke
The diabetes drug may offer better control than insulin for hyperglycemia, a common condition following stroke that leads to worse outcomes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 12, 2022 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
FDA OKs Extended-Release Exenatide for Children With T2D FDA OKs Extended-Release Exenatide for Children With T2D
This injectable medication is the second GLP-1 receptor agonist approved for pediatric type 2 diabetes, and the first with once-weekly administration.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Bydureon BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
WILMINGTON, Del.--(BUSINESS WIRE) July 23, 2021--AstraZeneca’s Bydureon BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 23, 2021 Category: Drugs & Pharmacology Source Type: news
Bydureon Bcise (exenatide)
Title: Bydureon Bcise (exenatide)Category: MedicationsCreated: 12/11/2020 12:00:00 AMLast Editorial Review: 12/11/2020 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 11, 2020 Category: Endocrinology Source Type: news
Drug Combo Offers Long-Term Glycemic Control in T2DM
FRIDAY, Nov. 6, 2020 -- For patients with type 2 diabetes and inadequate glycemic control, exenatide once weekly (QW) plus dapagliflozin shows clinically relevant efficacy and is well tolerated over 104 weeks, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2020 Category: Pharmaceuticals Source Type: news
Exenatide in T2DM in Spain: better outcomes, lower cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2019 Category: Drugs & Pharmacology Source Type: news
